Literature DB >> 20298215

The anti-allodynic alpha(2)delta ligand pregabalin inhibits the trafficking of the calcium channel alpha(2)delta-1 subunit to presynaptic terminals in vivo.

Claudia S Bauer1, Wahida Rahman, Alexandra Tran-van-Minh, Rafael Lujan, Anthony H Dickenson, Annette C Dolphin.   

Abstract

Neuropathic pain is caused by lesion or dysfunction of the peripheral sensory nervous system. Up-regulation of the voltage-gated Ca(2+) channel subunit alpha(2)delta-1 in DRG (dorsal root ganglion) neurons and the spinal cord correlates with the onset of neuropathic pain symptoms such as allodynia in several animal models of neuropathic pain. The clinically important anti-allodynic drugs gabapentin and pregabalin are alpha(2)delta-1 ligands, but how these drugs alleviate neuropathic pain is poorly understood. In the present paper, we review recent advances in our understanding of their molecular mechanisms.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20298215     DOI: 10.1042/BST0380525

Source DB:  PubMed          Journal:  Biochem Soc Trans        ISSN: 0300-5127            Impact factor:   5.407


  32 in total

Review 1.  The discovery and development of analgesics: new mechanisms, new modalities.

Authors:  Gillian Burgess; Dic Williams
Journal:  J Clin Invest       Date:  2010-11-01       Impact factor: 14.808

Review 2.  Calcium channel functions in pain processing.

Authors:  John Park; Z David Luo
Journal:  Channels (Austin)       Date:  2010-11-01       Impact factor: 2.581

3.  Overcoming obstacles to developing new analgesics.

Authors:  Clifford J Woolf
Journal:  Nat Med       Date:  2010-10-14       Impact factor: 53.440

4.  The antiallodynic action of pregabalin may depend on the suppression of spinal neuronal hyperexcitability in rats with spared nerve injury.

Authors:  Lei Ding; Jie Cai; Xiang-Yang Guo; Xiu-Li Meng; Guo-Gang Xing
Journal:  Pain Res Manag       Date:  2014-05-21       Impact factor: 3.037

5.  Recent advances in targeting ion channels to treat chronic pain.

Authors:  Edward B Stevens; Gary J Stephens
Journal:  Br J Pharmacol       Date:  2018-06       Impact factor: 8.739

6.  Systemic pregabalin attenuates sensorimotor responses and medullary glutamate release in inflammatory tooth pain model.

Authors:  N Narita; N Kumar; P S Cherkas; C Y Chiang; J O Dostrovsky; T J Coderre; B J Sessle
Journal:  Neuroscience       Date:  2012-05-17       Impact factor: 3.590

7.  Gabapentinoid Insensitivity after Repeated Administration is Associated with Down-Regulation of the α(2)δ-1 Subunit in Rats with Central Post-Stroke Pain Hypersensitivity.

Authors:  Yan Yang; Fei Yang; Fan Yang; Chun-Li Li; Yan Wang; Zhen Li; Yun-Fei Lu; Yao-Qing Yu; Han Fu; Ting He; Wei Sun; Rui-Rui Wang; Jun Chen
Journal:  Neurosci Bull       Date:  2016-01-19       Impact factor: 5.203

8.  Post-stroke pain hypersensitivity induced by experimental thalamic hemorrhage in rats is region-specific and demonstrates limited efficacy of gabapentin.

Authors:  Fei Yang; Han Fu; Yun-Fei Lu; Xiao-Liang Wang; Yan Yang; Fan Yang; Yao-Qing Yu; Wei Sun; Jia-Shuang Wang; Michael Costigan; Jun Chen
Journal:  Neurosci Bull       Date:  2014-11-05       Impact factor: 5.203

9.  Homology-guided mutational analysis reveals the functional requirements for antinociceptive specificity of collapsin response mediator protein 2-derived peptides.

Authors:  Aubin Moutal; Wennan Li; Yue Wang; Weina Ju; Shizhen Luo; Song Cai; Liberty François-Moutal; Samantha Perez-Miller; Jackie Hu; Erik T Dustrude; Todd W Vanderah; Vijay Gokhale; May Khanna; Rajesh Khanna
Journal:  Br J Pharmacol       Date:  2017-03-17       Impact factor: 8.739

10.  In vivo imaging reveals that pregabalin inhibits cortical spreading depression and propagation to subcortical brain structures.

Authors:  Stuart M Cain; Barry Bohnet; Jeffrey LeDue; Andrew C Yung; Esperanza Garcia; John R Tyson; Sascha R A Alles; Huili Han; Arn M J M van den Maagdenberg; Piotr Kozlowski; Brian A MacVicar; Terrance P Snutch
Journal:  Proc Natl Acad Sci U S A       Date:  2017-02-21       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.